New hope for lung cancer patients who Can't take chemo

NCT ID NCT07295821

Not yet recruiting Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

Summary

This study is testing a treatment plan for adults with a specific type of advanced, inoperable lung cancer who are not candidates for or refuse chemotherapy. The plan involves taking a targeted pill called osimertinib for about 12 weeks, followed by radiation therapy, and then continuing the pill long-term. The main goal is to see if this approach can control the cancer and keep it from getting worse.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Research Site

Beijing, 100021, China
Research Site

Beijing, 100730, China
Research Site

Changchun, 130021, China
Research Site

Changsha, 410013, China
Research Site

Chengdu, 610041, China
Research Site

Foshan, 528000, China
Research Site

Fuzhou, 350011, China
Research Site

Guangzhou, 510060, China
Research Site

Guangzhou, 510100, China
Research Site

Harbin, 150081, China
Research Site

Hefei, 230031, China
Research Site

Jinan, 250021, China
Research Site

Kunming, 650118, China
Research Site

Nanchang, 330006, China
Research Site

Qingdao, 110016, China
Research Site

Shanghai, 200120, China
Research Site

Shanghai, 200433, China
Research Site

Taiyuan, 030000, China
Research Site

Wenzhou, 325000, China
Research Site

Xuzhou, 221000, China

Conditions

Explore the condition pages connected to this study.

LUNG CANCER